TLR3基因变异乳腺癌发生发展中作用机制及患者临床特征与临床治疗的研究进展
Research Progress on the Mechanism of TLR3 Gene Mutation in the Occurrence and Development of Breast Cancer and the Clinical Characteristics and Clinical Treatment of Patients
DOI: 10.12677/acm.2024.1451666, PDF,   
作者: 项 磊, 马金柱*:内蒙古医科大学附属医院,内蒙古 呼和浩特
关键词: TLR3基因变异乳腺癌作用机制临床特征TLR3 Gene Variation Breast Cancer Mechanism of Action Clinical Characteristics
摘要: 本综述将深入探讨了TLR3基因变异在乳腺癌研究和治疗中的潜在作用机制和重要性。从乳腺癌的定义、分类和流行病学数据入手,突出了乳腺癌作为一种重要的癌症在全球范围内的危害和不断增加的趋势,详细分析了TLR3基因的功能、表达和与乳腺癌的关联,强调了其在乳腺癌免疫反应中的关键作用。在此技术上将进一步探讨TLR3基因变异与乳腺癌的关系,从多个角度分析了其潜在作用机制,强调TLR3基因变异可能通过影响TLR3通路的激活和抑制、对乳腺癌细胞生长、侵袭和转移的影响,以及其他可能的作用机制,对乳腺癌的发展产生影响。此外,本文还将进一步强调TLR3基因变异与患者临床特征之间的关系,包括基因型与表型的关联、临床病理特征与TLR3基因变异的相关性,以及患者预后与TLR3基因变异的关联。
Abstract: This review will delve into the potential mechanism and importance of TLR3 gene mutations in breast cancer research and treatment. Starting with the definition, classification and epidemiological data of breast cancer, it highlights the harm and increasing trend of breast cancer, which is a crucial cancer worldwide. It analyzes in detail the function, expression and association of TLR3 gene with breast cancer, emphasizing its key role in the immune response of breast cancer. Based on this, the review will further explore the relationship between TLR3 gene mutations and breast cancer, analyzing its potential mechanism from multiple perspectives. It emphasizes that TLR3 gene mutations may affect the development of breast cancer by influencing the activation and inhibition of TLR3 pathway, the growth, invasion and metastasis of breast cancer cells, and other possible mechanisms. In addition, this article will further emphasize the relationship between TLR3 gene mutations and patients’ clinical characteristics, including the correlation between genotype and phenotype, the correlation between clinical pathological features and TLR3 gene mutations, and the correlation between patient prognosis and TLR3 gene mutations.
文章引用:项磊, 马金柱. TLR3基因变异乳腺癌发生发展中作用机制及患者临床特征与临床治疗的研究进展[J]. 临床医学进展, 2024, 14(5): 2175-2180. https://doi.org/10.12677/acm.2024.1451666

参考文献

[1] Wu, Q., Nie, D.Y., Ba-Alawi, W., et al. (2022) PRMT Inhibition Induces a Viral Mimicry Response in Triple-Negative Breast Cancer. Nature Chemical Biology, 18, 821-830. [Google Scholar] [CrossRef] [PubMed]
[2] Huang, Z., He, A., Wang, J., et al. (2022) Toll-Like Receptor 3 Is a Potential Prognosis Marker and Associated with Immune Infiltration in Stomach Adenocarcinoma. Cancer Biomarkers, 34, 77-93. [Google Scholar] [CrossRef
[3] Afroz, R., Tanvir, E, M., Tania, M., et al. (2022) LPS/TLR4 Pathways in Breast Cancer: Insights into Cell Signalling. Current Medicinal Chemistry, 29, 2274-2289. [Google Scholar] [CrossRef] [PubMed]
[4] Escudero-Lourdes, C., Alvarado-Morales, I. and Tokar, E.J. (2022) Stem Cells as Target for Prostate Cancer Therapy: Opportunities and Challenges. Stem Cell Reviews and Reports, 18, 2833-2851. [Google Scholar] [CrossRef] [PubMed]
[5] Tan, C., Wei, Y., Ding, X., et al. (2022) Cell Senescence-Associated Genes Predict the Malignant Characteristics of Glioblastoma. Cancer Cell International, 22, Article No. 411. [Google Scholar] [CrossRef] [PubMed]
[6] Bareche, Y., Buisseret, L., Gruosso, T., et al. (2020) Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach. JNCI: Journal of the National Cancer Institute, 112, 708-719. [Google Scholar] [CrossRef] [PubMed]
[7] Le Naour, J., Liu, P., Zhao, L., et al. (2021) A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. Cancer Discovery, 11, 408-423. [Google Scholar] [CrossRef
[8] Borovcanin, M.M., Radosavljevic, G.D., Pantic, J., et al. (2021) Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity. Current Topics in Medicinal Chemistry, 21, 1471-1487. [Google Scholar] [CrossRef] [PubMed]
[9] Qu, Y., Cheng, B., Shao, N., et al. (2020) Prognostic Value of Immune-Related Genes in the Tumor Microenvironment of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. Aging, 12, 4757-4777. [Google Scholar] [CrossRef] [PubMed]
[10] Han, S., Yin, X., Wang, Y., et al. (2020) Co-Expression of HIF-1 and TLR3 Is Associated with Poor Prognosis in Oral Squamous Cell Carcinoma. International Journal of Clinical and Experimental Pathology, 13, 65-72.
[11] Lin, Y., Liu, S., Bian, L., et al. (2023) Bioinformatics Analysis of Immune Infiltration in Endometrial Carcinoma Tumors and Its Relationship with Prognosis. Cancer Diagnosis & Prognosis, 3, 416-427. [Google Scholar] [CrossRef] [PubMed]
[12] Nissen, M.S., Ryding, M., Meyer, M., et al. (2020) Autoimmune Encephalitis: Current Knowledge on Subtypes, Disease Mechanisms and Treatment. CNS & Neurological Disorders-Drug Targets, 19, 584-598. [Google Scholar] [CrossRef] [PubMed]
[13] Wang, Z. and Wu, X. (2020) Study and Analysis of Antitumor Resistance Mechanism of PD1/PD-L1 Immune Checkpoint Blocker. Cancer Medicine, 9, 8086-8121. [Google Scholar] [CrossRef] [PubMed]
[14] Wawrzyniak, D., Grabowska, M., Głodowicz, P., et al. (2020) Down-Regulation of Tenascin-C Inhibits Breast Cancer Cells Development by Cell Growth, Migration, and Adhesion Impairment. PLOS ONE, 15, e0237889. [Google Scholar] [CrossRef] [PubMed]
[15] Feng, W., Wang, Y., Chen, S., et al. (2020) Intra-Tumoral Heterogeneity and Immune Responses Predicts Prognosis of Gastric Cancer. Aging, 12, 24333-24344. [Google Scholar] [CrossRef] [PubMed]
[16] Le Naour, J., Thierry, S., Scuderi, S.A., et al. (2023) A Chemically Defined TLR3 Agonist with Anticancer Activity. OncoImmunology, 12, Article ID: 2227510. [Google Scholar] [CrossRef
[17] Manna, P.R., Ahmed, A.U., Molehin, D., et al. 2022 () Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein. Biomedicines, 10, Article 1313. [Google Scholar] [CrossRef] [PubMed]
[18] Tkach, M., Thalmensi, J., Timperi, E., et al. (2022) Extracellular Vesicles from Triple Negative Breast Cancer Promote Pro-Inflammatory Macrophages Associated with Better Clinical Outcome. Proceedings of the National Academy of Sciences of the United States of America, 119, e2107394119. [Google Scholar] [CrossRef] [PubMed]
[19] Shahverdi, M., Masoumi, J., Ghorbaninezhad, F., et al. (2022) The Modulatory Role of Dendritic Cell-T Cell Cross-Talk in Breast Cancer: Challenges and Prospects. Advances in Medical Sciences, 67, 353-363. [Google Scholar] [CrossRef] [PubMed]
[20] Dvornikova, K.A., Bystrova, E.Y., Platonova, O.N. and Churilov, L.P. (2020) Polymorphism of Toll-Like Receptor Genes and Autoimmune Endocrine Diseases. Autoimmunity Reviews, 19, Article ID: 102496. [Google Scholar] [CrossRef] [PubMed]
[21] Zhu, Z., Zhu, X., Yang, S., et al. (2020) Yin-Yang Effect of Tumour Cells in Breast Cancer: From Mechanism of Crosstalk Between Tumour-Associated Macrophages and Cancer-Associated Adipocytes. American Journal of Cancer Research, 10, 383-392.
[22] Florez-Alvarez, L., Ruiz-Perez, L., Taborda, N., et al. (2020) Toll-Like Receptors as a Therapeutic Target in Cancer, Infections and Inflammatory Diseases. Immunotherapy, 12, 311-322. [Google Scholar] [CrossRef] [PubMed]
[23] Liu, W., Zhang, C., Gong, X., et al. (2020) Prognostic Value of Immune-Related Genes in Laryngeal Squamous Cell Carcinoma. Translational Cancer Research, 9, Article 6287. [Google Scholar] [CrossRef] [PubMed]
[24] Chen, W., Lin, W., Wu, L., et al. (2022) A Novel Prognostic Predictor of Immune Microenvironment and Therapeutic Response in Kidney Renal Clear Cell Carcinoma Based on Necroptosis-Related Gene Signature. International Journal of Medical Sciences, 19, 377-392. [Google Scholar] [CrossRef] [PubMed]
[25] Zhu, S., Zhang, T., Zheng, L., et al. (2021) Combination Strategies to Maximize the Benefits of Cancer Immunotherapy. Journal of Hematology & Oncology, 14, Article No. 156. [Google Scholar] [CrossRef] [PubMed]
[26] Li, D. and Wu, M. (2021) Pattern Recognition Receptors in Health and Diseases. Signal Transduction and Targeted Therapy, 6, Article No. 291. [Google Scholar] [CrossRef] [PubMed]
[27] Huang, R., Sun, Z., Xian, S., et al. (2022) The Role of Toll-Like Receptors (TLRs) in Pan-Cancer. Annals of Medicine, 54, 1918-1937. [Google Scholar] [CrossRef] [PubMed]
[28] Sui, Q., Zhang, X., Chen, C., et al. (2022) Inflammation Promotes Resistance to Immune Checkpoint Inhibitors in High Microsatellite Instability Colorectal Cancer. Nature Communications, 13, Article No. 7316. [Google Scholar] [CrossRef] [PubMed]